Ovarian Cancer Clinical Trial

Research Study in Patients With Advanced Ovarian Epithelial Cancer

Summary

This research trial studies tissue samples from patients with ovarian cancer in the laboratory. Analyzing tissue samples from patients in the laboratory may help doctors learn more about cancer.

View Full Description

Full Description

OBJECTIVES:

I. Utilize array comparative genomic hybridization and Taqman analyses, a quantitative genomic polymerase chain reaction, to validate the observation that a gain in chromosome 8q is predictive of shorter progression-free survival in patients with primary grade 2 or grade 3 advanced serous papillary ovarian cancer.

II. Utilize these analyses to determine whether a gain in chromosome 8q is predictive of worse overall survival in these patients.

III. Utilize these analyses to determine whether other previously identified chromosomal changes (3q gain, 7q gain, 16q loss, and 17pter-q21 loss) predict outcome in these patients and the association between these changes and clinical characteristics.

IV. Utilize these analyses to identify up to 5 additional chromosomal changes and their association that may predict outcome (progression-free and overall survival) in these patients.

OUTLINE:

Genomic DNA is isolated from optimal cutting temperature (OCT)-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Stage III or IV, high-grade (grade 2 or 3) ovarian cancers

No borderline or low-grade (grade 1) tumors

Tissue from predominately serous ovarian cancer only

No clear cell, endometrioid, mucinous, transitional cell, or mixed without predominant serous component
Tissue obtained during prior optimal or suboptimal cytoreductive surgery
Must be enrolled on GOG-0136 and a GOG front-line paclitaxel/platinum chemotherapy trial
Frozen tissue and hematoxylin-eosin stained section from the ovary obtained at initial surgery
Performance status - GOG 0-2

Study is for people with:

Ovarian Cancer

Study ID:

NCT00053235

Recruitment Status:

Withdrawn

Sponsor:

Gynecologic Oncology Group

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Gynecologic Oncology Group
Philadelphia Pennsylvania, 19103, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Study ID:

NCT00053235

Recruitment Status:

Withdrawn

Sponsor:


Gynecologic Oncology Group

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider